In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens
We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and flucytosine (FCU) in comparison to voriconazole (VOR) as a triazole derivative and caspofungin (CAS) as an echinocandin against 114 Candida spp. isolated from different cultures (blood, urine, spu...
Gespeichert in:
| Veröffentlicht in: | Japanese Journal of Infectious Diseases 2007/09/27, Vol.60(5), pp.302-304 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 304 |
|---|---|
| container_issue | 5 |
| container_start_page | 302 |
| container_title | Japanese Journal of Infectious Diseases |
| container_volume | 60 |
| creator | Özçelik, Berrin Kaynak, Fatma Cesur, Salih Sipahi, Bilge Sultan, Nedim |
| description | We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and flucytosine (FCU) in comparison to voriconazole (VOR) as a triazole derivative and caspofungin (CAS) as an echinocandin against 114 Candida spp. isolated from different cultures (blood, urine, sputum). The most common species of identified Candida were C. albicans (88), followed by C. parapsilosis (8), C. glabrata (7), C. tropicalis (6), C. famata (2), C. kefyr (2), and C. sake (1). The Clinical and Laboratory Standards Institute M 27-A method was used to evaluate the activity of antifungal agents. The minimal inhibitory concentrations of the strains were evaluated by RPMI 1640 medium using a microdilution method. Of 114 isolates, 100% were sensitive to AmpB, VOR, and CAS, 1.75% showed intermediate resistant to FCU also 0.87% showed intermediate resistant to FLU, and 2.63% were fully resistant to FLU and FCU. These results suggest that KET, AmpB, CAS, and VOR demonstrated excellent activity against all Candida spp. Taken together; these antifungal agents should be effective in the treatment of a broad range of Candida infections. |
| doi_str_mv | 10.7883/yoken.JJID.2007.302 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68292293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68292293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-e6652e9643d5235c4b2fc9b6c230fd30cee077261bb36f77825b1efe1a3d96f53</originalsourceid><addsrcrecordid>eNpVkc1u1DAYRSMEoqXwBEjIK3YZ_JM4yXKUtpCqEosOZWk5zucZl8QOtqeovCIvhTMzKmLjv-_ck0g3y94TvKrqmn16cj_Arm5uussVxbhaMUxfZOekrouc1oy_TGdWFDlnuDjL3oTwgDEtS4JfZ2ckCUhdsfPsT2fRvYneobWK5tFEAwE5je6dN8pZ-duNgGRAEm28Od4uwZtHmeA0sANqZZid3tutsQfQoiu1M9apNExP38EDat00Sw8D-mXiDm12LsDykTs3AVrbaJa4HNF6CzYmxVYaG2IyJ8Mg0d0MavmtLrhRxmTR3k2oHY01KqUO4wlseJu90nIM8O60X2Tfrq827Zf89uvnrl3f5qrERcyB85JCwws2lJSVquipVk3PFWVYDwwrAFxVlJO-Z1xXVU3LnoAGItnQcF2yi-zj0Tt793MPIYrJBAXjKC24fRC8pg2lDUsgO4LKuxA8aDF7M0n_JAgWS4fi0KFYOhRLhyJ1mFIfTvp9P8HwL3MqLQHdEXgIUW7hGZA-GjXCScqxKJflP_kzo3bSC7DsL8hWt9k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68292293</pqid></control><display><type>article</type><title>In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Freely Accessible Japanese Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Özçelik, Berrin ; Kaynak, Fatma ; Cesur, Salih ; Sipahi, Bilge ; Sultan, Nedim</creator><creatorcontrib>Özçelik, Berrin ; Kaynak, Fatma ; Cesur, Salih ; Sipahi, Bilge ; Sultan, Nedim</creatorcontrib><description>We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and flucytosine (FCU) in comparison to voriconazole (VOR) as a triazole derivative and caspofungin (CAS) as an echinocandin against 114 Candida spp. isolated from different cultures (blood, urine, sputum). The most common species of identified Candida were C. albicans (88), followed by C. parapsilosis (8), C. glabrata (7), C. tropicalis (6), C. famata (2), C. kefyr (2), and C. sake (1). The Clinical and Laboratory Standards Institute M 27-A method was used to evaluate the activity of antifungal agents. The minimal inhibitory concentrations of the strains were evaluated by RPMI 1640 medium using a microdilution method. Of 114 isolates, 100% were sensitive to AmpB, VOR, and CAS, 1.75% showed intermediate resistant to FCU also 0.87% showed intermediate resistant to FLU, and 2.63% were fully resistant to FLU and FCU. These results suggest that KET, AmpB, CAS, and VOR demonstrated excellent activity against all Candida spp. Taken together; these antifungal agents should be effective in the treatment of a broad range of Candida infections.</description><identifier>ISSN: 1344-6304</identifier><identifier>EISSN: 1884-2836</identifier><identifier>DOI: 10.7883/yoken.JJID.2007.302</identifier><identifier>PMID: 17881873</identifier><language>eng</language><publisher>Japan: National Institute of Infectious Diseases</publisher><subject>Antifungal Agents - pharmacology ; Candida - drug effects ; Candida - isolation & purification ; Candidiasis - blood ; Candidiasis - microbiology ; Candidiasis - urine ; Drug Resistance, Fungal ; Echinocandins - pharmacology ; Humans ; Lipopeptides ; Microbial Sensitivity Tests ; Pyrimidines - pharmacology ; Sputum - microbiology ; Triazoles - pharmacology ; Voriconazole</subject><ispartof>Japanese Journal of Infectious Diseases, 2007/09/27, Vol.60(5), pp.302-304</ispartof><rights>2007 Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-e6652e9643d5235c4b2fc9b6c230fd30cee077261bb36f77825b1efe1a3d96f53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17881873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Özçelik, Berrin</creatorcontrib><creatorcontrib>Kaynak, Fatma</creatorcontrib><creatorcontrib>Cesur, Salih</creatorcontrib><creatorcontrib>Sipahi, Bilge</creatorcontrib><creatorcontrib>Sultan, Nedim</creatorcontrib><title>In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens</title><title>Japanese Journal of Infectious Diseases</title><addtitle>Jpn J Infect Dis</addtitle><description>We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and flucytosine (FCU) in comparison to voriconazole (VOR) as a triazole derivative and caspofungin (CAS) as an echinocandin against 114 Candida spp. isolated from different cultures (blood, urine, sputum). The most common species of identified Candida were C. albicans (88), followed by C. parapsilosis (8), C. glabrata (7), C. tropicalis (6), C. famata (2), C. kefyr (2), and C. sake (1). The Clinical and Laboratory Standards Institute M 27-A method was used to evaluate the activity of antifungal agents. The minimal inhibitory concentrations of the strains were evaluated by RPMI 1640 medium using a microdilution method. Of 114 isolates, 100% were sensitive to AmpB, VOR, and CAS, 1.75% showed intermediate resistant to FCU also 0.87% showed intermediate resistant to FLU, and 2.63% were fully resistant to FLU and FCU. These results suggest that KET, AmpB, CAS, and VOR demonstrated excellent activity against all Candida spp. Taken together; these antifungal agents should be effective in the treatment of a broad range of Candida infections.</description><subject>Antifungal Agents - pharmacology</subject><subject>Candida - drug effects</subject><subject>Candida - isolation & purification</subject><subject>Candidiasis - blood</subject><subject>Candidiasis - microbiology</subject><subject>Candidiasis - urine</subject><subject>Drug Resistance, Fungal</subject><subject>Echinocandins - pharmacology</subject><subject>Humans</subject><subject>Lipopeptides</subject><subject>Microbial Sensitivity Tests</subject><subject>Pyrimidines - pharmacology</subject><subject>Sputum - microbiology</subject><subject>Triazoles - pharmacology</subject><subject>Voriconazole</subject><issn>1344-6304</issn><issn>1884-2836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1u1DAYRSMEoqXwBEjIK3YZ_JM4yXKUtpCqEosOZWk5zucZl8QOtqeovCIvhTMzKmLjv-_ck0g3y94TvKrqmn16cj_Arm5uussVxbhaMUxfZOekrouc1oy_TGdWFDlnuDjL3oTwgDEtS4JfZ2ckCUhdsfPsT2fRvYneobWK5tFEAwE5je6dN8pZ-duNgGRAEm28Od4uwZtHmeA0sANqZZid3tutsQfQoiu1M9apNExP38EDat00Sw8D-mXiDm12LsDykTs3AVrbaJa4HNF6CzYmxVYaG2IyJ8Mg0d0MavmtLrhRxmTR3k2oHY01KqUO4wlseJu90nIM8O60X2Tfrq827Zf89uvnrl3f5qrERcyB85JCwws2lJSVquipVk3PFWVYDwwrAFxVlJO-Z1xXVU3LnoAGItnQcF2yi-zj0Tt793MPIYrJBAXjKC24fRC8pg2lDUsgO4LKuxA8aDF7M0n_JAgWS4fi0KFYOhRLhyJ1mFIfTvp9P8HwL3MqLQHdEXgIUW7hGZA-GjXCScqxKJflP_kzo3bSC7DsL8hWt9k</recordid><startdate>20070927</startdate><enddate>20070927</enddate><creator>Özçelik, Berrin</creator><creator>Kaynak, Fatma</creator><creator>Cesur, Salih</creator><creator>Sipahi, Bilge</creator><creator>Sultan, Nedim</creator><general>National Institute of Infectious Diseases</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070927</creationdate><title>In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens</title><author>Özçelik, Berrin ; Kaynak, Fatma ; Cesur, Salih ; Sipahi, Bilge ; Sultan, Nedim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-e6652e9643d5235c4b2fc9b6c230fd30cee077261bb36f77825b1efe1a3d96f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antifungal Agents - pharmacology</topic><topic>Candida - drug effects</topic><topic>Candida - isolation & purification</topic><topic>Candidiasis - blood</topic><topic>Candidiasis - microbiology</topic><topic>Candidiasis - urine</topic><topic>Drug Resistance, Fungal</topic><topic>Echinocandins - pharmacology</topic><topic>Humans</topic><topic>Lipopeptides</topic><topic>Microbial Sensitivity Tests</topic><topic>Pyrimidines - pharmacology</topic><topic>Sputum - microbiology</topic><topic>Triazoles - pharmacology</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Özçelik, Berrin</creatorcontrib><creatorcontrib>Kaynak, Fatma</creatorcontrib><creatorcontrib>Cesur, Salih</creatorcontrib><creatorcontrib>Sipahi, Bilge</creatorcontrib><creatorcontrib>Sultan, Nedim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese Journal of Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Özçelik, Berrin</au><au>Kaynak, Fatma</au><au>Cesur, Salih</au><au>Sipahi, Bilge</au><au>Sultan, Nedim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens</atitle><jtitle>Japanese Journal of Infectious Diseases</jtitle><addtitle>Jpn J Infect Dis</addtitle><date>2007-09-27</date><risdate>2007</risdate><volume>60</volume><issue>5</issue><spage>302</spage><epage>304</epage><pages>302-304</pages><artnum>JJID.2007.302</artnum><issn>1344-6304</issn><eissn>1884-2836</eissn><abstract>We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and flucytosine (FCU) in comparison to voriconazole (VOR) as a triazole derivative and caspofungin (CAS) as an echinocandin against 114 Candida spp. isolated from different cultures (blood, urine, sputum). The most common species of identified Candida were C. albicans (88), followed by C. parapsilosis (8), C. glabrata (7), C. tropicalis (6), C. famata (2), C. kefyr (2), and C. sake (1). The Clinical and Laboratory Standards Institute M 27-A method was used to evaluate the activity of antifungal agents. The minimal inhibitory concentrations of the strains were evaluated by RPMI 1640 medium using a microdilution method. Of 114 isolates, 100% were sensitive to AmpB, VOR, and CAS, 1.75% showed intermediate resistant to FCU also 0.87% showed intermediate resistant to FLU, and 2.63% were fully resistant to FLU and FCU. These results suggest that KET, AmpB, CAS, and VOR demonstrated excellent activity against all Candida spp. Taken together; these antifungal agents should be effective in the treatment of a broad range of Candida infections.</abstract><cop>Japan</cop><pub>National Institute of Infectious Diseases</pub><pmid>17881873</pmid><doi>10.7883/yoken.JJID.2007.302</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1344-6304 |
| ispartof | Japanese Journal of Infectious Diseases, 2007/09/27, Vol.60(5), pp.302-304 |
| issn | 1344-6304 1884-2836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68292293 |
| source | J-STAGE Free; MEDLINE; Freely Accessible Japanese Titles; EZB-FREE-00999 freely available EZB journals |
| subjects | Antifungal Agents - pharmacology Candida - drug effects Candida - isolation & purification Candidiasis - blood Candidiasis - microbiology Candidiasis - urine Drug Resistance, Fungal Echinocandins - pharmacology Humans Lipopeptides Microbial Sensitivity Tests Pyrimidines - pharmacology Sputum - microbiology Triazoles - pharmacology Voriconazole |
| title | In Vitro Activities of Voriconazole as a Triazole Derivative and Caspofungin as an Echinocandin Were Compared with Those of Some Antifungal Agents against Candida Species Isolated from Clinical Specimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A40%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Activities%20of%20Voriconazole%20as%20a%20Triazole%20Derivative%20and%20Caspofungin%20as%20an%20Echinocandin%20Were%20Compared%20with%20Those%20of%20Some%20Antifungal%20Agents%20against%20Candida%20Species%20Isolated%20from%20Clinical%20Specimens&rft.jtitle=Japanese%20Journal%20of%20Infectious%20Diseases&rft.au=%C3%96z%C3%A7elik,%20Berrin&rft.date=2007-09-27&rft.volume=60&rft.issue=5&rft.spage=302&rft.epage=304&rft.pages=302-304&rft.artnum=JJID.2007.302&rft.issn=1344-6304&rft.eissn=1884-2836&rft_id=info:doi/10.7883/yoken.JJID.2007.302&rft_dat=%3Cproquest_cross%3E68292293%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68292293&rft_id=info:pmid/17881873&rfr_iscdi=true |